Baxter to Form New Global Innovation and R&D Center
News Oct 10, 2014
Baxter International Inc. has announced plans to form a new global innovation and research and development (R&D) center in Cambridge, Mass., for Baxter's biopharmaceuticals business, which is expected to become a separate, independent global company known as Baxalta Incorporated in mid-2015.
The business selected the Cambridge biotech community as the primary location for its global innovation and R&D operations after a global search. The new location will position the company to enhance patient care by advancing and building its robust innovation pipeline, which is centered on core areas of expertise in hematology, immunology, and through technology platforms like gene therapy and biosimilars.
The company expects to bring together approximately 400 R&D employees at the innovation center, as well as its business development, oncology and biosimilars teams. The R&D positions that will relocate to the new center are currently based in California and Europe. The new biopharmaceutical company will maintain certain R&D operations at its location in Vienna, Austria, and will have its corporate headquarters in northern Illinois.
"Critical elements to our success as an independent biopharmaceuticals company will be our ability to accelerate innovation, optimize R&D productivity, and deliver on our promise to patients. Joining this unmatched biotech community is an important step," said Ludwig Hantson, Ph.D., president of Baxter BioScience.
"Our new innovation center will increase R&D collaboration and efficiency, connect us directly to a rich pool of talent in new and emerging biotech areas, and strengthen our ability to drive programs forward in cooperation with current and future partners," said John Orloff, M.D., vice president and global head of research and development for Baxter BioScience.
The company expects to open the first phase of the 200,000-square feet in leased space later this year, and will continue to transition work to the new facility over the next two years to ensure continuity of current programs.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
New Bioprocessing Technique Set to Revolutionize Cell CultureNews
A technique which revolutionises cell culture by allowing the continuous production and collection of cells, has been developed by scientists at Newcastle University. The Newcastle team have developed a coating that allows individual stromal cells to “peel away” from the surface on which they are grown.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE